Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –– Enrolling approximately one patient per week ...
Charles Schwab Investment Management Inc. Purchases 9,441 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS)
Charles Schwab Investment Management Inc. lifted its holdings in IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) by 6.4% in ...
Pharmabiz9h
EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications
EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...
Le Lézard3h
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...